Reimbursement Cuts Just Erased Your Margin Foundation

You built your growth model on a reimbursement rate that just got axed. Now your CAC is underwater, your LTV assumptions are garbage, and your board is asking difficult questions.

Customer Acquisition Costs Are Spiraling Into Unsustainable Territory

Direct-to-consumer CAC is climbing while insurance reimbursement shrinks. The brands that survive will be the ones that diversify revenue faster than their competition.

You're Competing On Price In A Market That Rewards Clinical Positioning

Consumers don't buy telehealth because it's cheaper. They buy it because they trust the clinical rigor. But your marketing is all CAC optimization and price positioning.

Telehealth reimbursement arbitrage and payer mix optimization

Direct-to-consumer vs. B2B vs. B2B2C unit economics

Clinical differentiation in crowded verticals (mental health, dermatology, primary care)

Retention economics for subscription vs. visit-based models

Regulatory compliance in experimentation (FDA claims, telehealth licensing)

Telehealth Unit Economics: Is Your Model Reimbursement-Proof?

Model your blended reimbursement rate, plug in 3 policy scenarios, and know in 5 minutes whether your growth plan survives regulatory change.

The 3 Revenue Diversification Strategies Winning Telehealth Brands Use

The brands that survive reimbursement volatility aren't the ones who fight it. They're the ones who made it irrelevant.

How to Position Clinical Rigor in a Race-to-the-Bottom Market

When every competitor claims "board-certified" and "evidence-based," differentiation collapses to price. Unless you know the positioning play they can't copy.